The use of fecal calprotectin testing in ...
Document type :
Article dans une revue scientifique: Article original
PMID :
Permalink :
Title :
The use of fecal calprotectin testing in paediatric disorders: a position paper of the european society for paediatric gastroenterology and nutrition gastroenterology committee
Author(s) :
Ribes-Koninckx, Carmen [Auteur]
Donat, Ester [Auteur]
Benninga, Marc A. [Auteur]
Broekaert, Ilse J. [Auteur]
Gottrand, fréderic [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Kolho, Kaija-Leena [Auteur]
Lionetti, Paolo [Auteur]
Miele, Erasmo [Auteur]
Orel, Rok [Auteur]
Papadopoulou, Alexandra [Auteur]
Pienar, Corina [Auteur]
Schappi, Michela G. [Auteur]
Wilschanski, Michael [Auteur]
Thapar, Nikhil [Auteur]
Donat, Ester [Auteur]
Benninga, Marc A. [Auteur]
Broekaert, Ilse J. [Auteur]
Gottrand, fréderic [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Kolho, Kaija-Leena [Auteur]
Lionetti, Paolo [Auteur]
Miele, Erasmo [Auteur]
Orel, Rok [Auteur]
Papadopoulou, Alexandra [Auteur]
Pienar, Corina [Auteur]
Schappi, Michela G. [Auteur]
Wilschanski, Michael [Auteur]
Thapar, Nikhil [Auteur]
Journal title :
Journal of Pediatric Gastroenterology and Nutrition
Abbreviated title :
J Pediatr Gastroenterol Nutr
Volume number :
72
Pages :
617-640
Publication date :
2021-04-01
ISSN :
1536-4801
Keyword(s) :
position paper
intestine
inflammatory bowel disease
Crohn disease
fecal calprotectin
inflammation
ulcerative colitis
intestine
inflammatory bowel disease
Crohn disease
fecal calprotectin
inflammation
ulcerative colitis
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
OBJECTIVE: The aim of the study was to review the evidence regarding the clinical use and value of fecal calprotectin (FC) measurements in different gastrointestinal disorders in children.
METHODS: A literature search was ...
Show more >OBJECTIVE: The aim of the study was to review the evidence regarding the clinical use and value of fecal calprotectin (FC) measurements in different gastrointestinal disorders in children. METHODS: A literature search was conducted in the PubMed, MEDLINE, EMBASE, and Cochrane databases until October 31, 2019. Subtopics were identified and each assigned to individual authors. RESULTS: A total of 28 recommendations were voted on using the nominal voting technique. Recommendations are given related to sampling, measurement methods, and results interpretation. The 14 authors anonymously voted on each recommendation using a 9-point scale (1 strongly disagree to 9 fully agree). Consensus was considered achieved if at least 75% of the authors voted 6, 7, 8, or 9. CONCLUSIONS: Consensus was reached for all recommendations. Limitations for the use of FC in clinical practice include variability in extraction methodology, performance of test kits as well as the need to establish local reference ranges because of the influence of individual factors, such as age, diet, microbiota, and drugs. The main utility of FC measurement at present is in the diagnosis and monitoring of inflammatory bowel disease (IBD) as well as to differentiate it from functional gastrointestinal disorders (FAPDs). FC, however, has neither utility in the diagnosis of infantile colic nor to differentiate between functional and organic constipation. A rise in FC concentration, may alert to the risk of developing necrotizing enterocolitis and help identifying gastrointestinal involvement in children with Henoch-Schönlein purpura. FC measurement is of little value in Cow's Milk Protein Allergy, coeliac disease (CD), and cystic fibrosis. FC does neither help to distinguish bacterial from viral acute gastroenteritis (AGE), nor to diagnose Helicobacter Pylori infection, small intestinal bacterial overgrowth (SIBO), acute appendicitis (AA), or intestinal polyps.Show less >
Show more >OBJECTIVE: The aim of the study was to review the evidence regarding the clinical use and value of fecal calprotectin (FC) measurements in different gastrointestinal disorders in children. METHODS: A literature search was conducted in the PubMed, MEDLINE, EMBASE, and Cochrane databases until October 31, 2019. Subtopics were identified and each assigned to individual authors. RESULTS: A total of 28 recommendations were voted on using the nominal voting technique. Recommendations are given related to sampling, measurement methods, and results interpretation. The 14 authors anonymously voted on each recommendation using a 9-point scale (1 strongly disagree to 9 fully agree). Consensus was considered achieved if at least 75% of the authors voted 6, 7, 8, or 9. CONCLUSIONS: Consensus was reached for all recommendations. Limitations for the use of FC in clinical practice include variability in extraction methodology, performance of test kits as well as the need to establish local reference ranges because of the influence of individual factors, such as age, diet, microbiota, and drugs. The main utility of FC measurement at present is in the diagnosis and monitoring of inflammatory bowel disease (IBD) as well as to differentiate it from functional gastrointestinal disorders (FAPDs). FC, however, has neither utility in the diagnosis of infantile colic nor to differentiate between functional and organic constipation. A rise in FC concentration, may alert to the risk of developing necrotizing enterocolitis and help identifying gastrointestinal involvement in children with Henoch-Schönlein purpura. FC measurement is of little value in Cow's Milk Protein Allergy, coeliac disease (CD), and cystic fibrosis. FC does neither help to distinguish bacterial from viral acute gastroenteritis (AGE), nor to diagnose Helicobacter Pylori infection, small intestinal bacterial overgrowth (SIBO), acute appendicitis (AA), or intestinal polyps.Show less >
Language :
Anglais
Peer reviewed article :
Oui
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
CHU Lille
Inserm
Université de Lille
Inserm
Université de Lille
Submission date :
2021-07-06T12:50:06Z
2024-03-05T10:49:00Z
2024-03-05T10:49:00Z